心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2014年
4期
436-439
,共4页
阿丽娅·艾依提%米日古丽·热合曼%涂良珍
阿麗婭·艾依提%米日古麗·熱閤曼%塗良珍
아려아·애의제%미일고려·열합만%도량진
高血压%治疗效果%氨氯地平%特拉唑嗪
高血壓%治療效果%氨氯地平%特拉唑嗪
고혈압%치료효과%안록지평%특랍서진
Hypertension%Treatment outcome%Amlodipine%Terazosin
目的:观察氨氯地平联合特拉唑嗪治疗中老年男性原发性高血压的短期临床疗效及安全性。方法:选择我院2011年1月~2012年2月收治的患有原发性高血压的中老年男性患者64例,随机分为氨氯地平组(单用氨氯地平治疗)和联合用药组(采用氨氯地平联合特拉唑嗪治疗),每组各32例。结果:联合用药组总有效率为93.75%,明显高于氨氯地平组的65.63%(P =0.028);两组治疗后收缩压(SBP)、舒张压(DBP)、总胆固醇(TC)、甘油三酯(TG)及空腹血糖(FPG)水平均明显降低(P <0.05~<0.01);与氨氯地平组比较,联合用药组降低更为显著[SBP:(138.55±7.96)mmHg 比(110.65±7.28)mmHg,DBP:(93.35±5.86)mmHg 比(80.11±5.93) mmHg,TC:(5.67±0.76)mmol/L 比(4.22±0.63)mmol/L,TG:(2.67±0.86)mmol/L 比(2.01±0.75) mmol/L,FBG:(5.69±0.86)mmol/L 比(4.31±0.58)mmol/L],P 均<0.05;联合用药组不良反应发生率(6.25%)明显低于氨氯地平组(18.75%),P <0.05。结论:氨氯地平联合特拉唑嗪治疗中老年男性原发性高血压临床效果显著,可有效降低患者收缩压和舒张压,不良反应少,值得临床推广。
目的:觀察氨氯地平聯閤特拉唑嗪治療中老年男性原髮性高血壓的短期臨床療效及安全性。方法:選擇我院2011年1月~2012年2月收治的患有原髮性高血壓的中老年男性患者64例,隨機分為氨氯地平組(單用氨氯地平治療)和聯閤用藥組(採用氨氯地平聯閤特拉唑嗪治療),每組各32例。結果:聯閤用藥組總有效率為93.75%,明顯高于氨氯地平組的65.63%(P =0.028);兩組治療後收縮壓(SBP)、舒張壓(DBP)、總膽固醇(TC)、甘油三酯(TG)及空腹血糖(FPG)水平均明顯降低(P <0.05~<0.01);與氨氯地平組比較,聯閤用藥組降低更為顯著[SBP:(138.55±7.96)mmHg 比(110.65±7.28)mmHg,DBP:(93.35±5.86)mmHg 比(80.11±5.93) mmHg,TC:(5.67±0.76)mmol/L 比(4.22±0.63)mmol/L,TG:(2.67±0.86)mmol/L 比(2.01±0.75) mmol/L,FBG:(5.69±0.86)mmol/L 比(4.31±0.58)mmol/L],P 均<0.05;聯閤用藥組不良反應髮生率(6.25%)明顯低于氨氯地平組(18.75%),P <0.05。結論:氨氯地平聯閤特拉唑嗪治療中老年男性原髮性高血壓臨床效果顯著,可有效降低患者收縮壓和舒張壓,不良反應少,值得臨床推廣。
목적:관찰안록지평연합특랍서진치료중노년남성원발성고혈압적단기림상료효급안전성。방법:선택아원2011년1월~2012년2월수치적환유원발성고혈압적중노년남성환자64례,수궤분위안록지평조(단용안록지평치료)화연합용약조(채용안록지평연합특랍서진치료),매조각32례。결과:연합용약조총유효솔위93.75%,명현고우안록지평조적65.63%(P =0.028);량조치료후수축압(SBP)、서장압(DBP)、총담고순(TC)、감유삼지(TG)급공복혈당(FPG)수평균명현강저(P <0.05~<0.01);여안록지평조비교,연합용약조강저경위현저[SBP:(138.55±7.96)mmHg 비(110.65±7.28)mmHg,DBP:(93.35±5.86)mmHg 비(80.11±5.93) mmHg,TC:(5.67±0.76)mmol/L 비(4.22±0.63)mmol/L,TG:(2.67±0.86)mmol/L 비(2.01±0.75) mmol/L,FBG:(5.69±0.86)mmol/L 비(4.31±0.58)mmol/L],P 균<0.05;연합용약조불량반응발생솔(6.25%)명현저우안록지평조(18.75%),P <0.05。결론:안록지평연합특랍서진치료중노년남성원발성고혈압림상효과현저,가유효강저환자수축압화서장압,불량반응소,치득림상추엄。
Objective:To observe the short-term therapeutic effect and safety of amlodipine combined terazosin on middle and old aged male patients with essential hypertension (EH).Methods:A total of 64 middle and old aged male EH patients treated in our hospital from Jan 2011 to Feb 2012 were enrolled.They were randomly and equally divided into amlodipine group and combined therapy group (received amlodipine combined terazosin treatment).Re-sults:Total effective rate of combined therapy group (93.75%)was significantly higher than that of amlodipine group (65.63%),P =0.028;there were significant reductions in levels of systolic blood pressure (SBP),diastolic blood pressure (DBP),total cholesterol (TC),triglyceride (TG)and fasting plasma glucose (FPG)in both groups after treatment (P <0.05~<0.01),compared with amlodipine group,there were more significant reductions in these indexes [SBP:(138.55±7.96)mmHg vs.(110.65±7.28)mmHg,DBP:(93.35±5.86)mmHg vs.(80.11 ±5.93)mmHg,TC:(5.67±0.76)mmol/L vs.(4.22±0.63)mmol/L,TG:(2.67±0.86)mmol/L vs.(2.01± 0.75)mmol/L,FBG: (5.69±0.86)mmol/L vs.(4.31±0.58)mmol/L]in combined therapy group,P <0.05 all;incidence rate of adverse reactions in combined therapy group (6.25%)was significantly lower than that of am-lodipine group (18.75%),P <0.05. Conclusion:Amlodipine combined terazosin possesses more therapeutic effect in middle and old aged male patients with essential hypertension.It can effectively reduce systolic and diastolic blood pressure;the adverse reactions are fewer,so it's worth extending in clinic.